TNFRSF17 and Miyoshi myopathy: In the Bluebird study NCT02658929, 33 patients with relapsed/refractory MM were treated with anti-BCMA CAR T-cells (bb2121) in a dose/escalation study (50–800 × 106 cells/kg) (31).